玛伐凯泰(Mavacamten) - 药物靶点：Cardiac myosin_在研适应症：梗阻性肥厚型心肌病，非梗阻性肥厚型心肌病，射血分数保留型心力衰竭_专利_临床

概要

基本信息

药物类型

小分子化药

别名

MAVA、MAVA-Myokardia、HCM 1

+ [6]

靶点

Cardiac myosin

作用机制

心肌肌球蛋白复合体抑制剂

治疗领域

心血管疾病

在研适应症

梗阻性肥厚型心肌病非梗阻性肥厚型心肌病射血分数保留型心力衰竭+ [1]

非在研适应症-

原研机构

Bristol Myers Squibb Co.

在研机构

BMS Korea Co. Ltd.

Bristol Myers Squibb Co.

上海联拓生物科技有限公司

+ [4]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2022-04-28),

梗阻性肥厚型心肌病

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、优先审评 (中国)、突破性疗法 (中国)、孤儿药 (韩国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C15H19N3O2

InChIKeyRLCLASQCAPXVLM-NSHDSACASA-N

CAS号1642288-47-8

关联

34

项与玛伐凯泰相关的临床试验

NCT06146660

/ RecruitingN/A

CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.

开始日期2024-07-24

申办/合作机构

Bristol Myers Squibb Co.

NCT06338202

/ RecruitingN/A

Real-World Effectiveness of MAVacamtEN in Canada (MAVEN): A Retrospective Physician Survey of Patient Charts

The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada.

开始日期2024-06-26

申办/合作机构

Bristol Myers Squibb Co.

NCT06551129

/ RecruitingN/A

Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study

This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.

开始日期2024-05-10

申办/合作机构

Bristol Myers Squibb Co.

100 项与玛伐凯泰相关的临床结果

登录后查看更多信息

100 项与玛伐凯泰相关的转化医学

登录后查看更多信息

100 项与玛伐凯泰相关的专利（医药）

登录后查看更多信息

268

项与玛伐凯泰相关的文献（医药）

2025-02-01·AMERICAN JOURNAL OF CARDIOLOGY

A Multicenter Evaluation of the Impact of Therapies on Deep Learning-Based Electrocardiographic Hypertrophic Cardiomyopathy Markers

Article

作者: Gaballa, Andrew ; Dhingra, Lovedeep S ; Sen, Sounok ; Mehra, Nandini ; Krumholz, Harlan M ; Bryde, Robyn ; Desai, Milind Y ; Ali, Adel H ; Krumholz, Harlan M. ; Sangha, Veer ; Oikonomou, Evangelos K ; Martinez, Matthew W ; Aminorroaya, Arya ; Kramer, Christopher M ; Khera, Rohan

Artificial intelligence-enhanced electrocardiography (AI-ECG) can identify hypertrophic cardiomyopathy (HCM) on 12-lead ECGs and offers a novel way to monitor treatment response. Although the surgical or percutaneous reduction of the interventricular septum (SRT) represented initial HCM therapies, mavacamten offers an oral alternative. We aimed to assess the use of AI-ECG as a strategy to evaluate biologic responses to SRT and mavacamten. We applied an AI-ECG model for HCM detection to electrocardiography images from patients who underwent SRT across 3 sites: Yale New Haven Health System (YNHHS), Cleveland Clinic Foundation (CCF), and Atlantic Health System (AHS) and to electrocardiography images from patients receiving mavacamten at YNHHS. A total of 70 patients underwent SRT at YNHHS, 100 at CCF, and 145 at AHS. At YNHHS, there was no significant change in the AI-ECG HCM score before versus after SRT (before SRT: median 0.55 [interquartile range 0.24 to 0.77] vs after SRT: 0.59 [0.40 to 0.75]). The AI-ECG HCM scores also did not improve after SRT at CCF (0.61 [0.32 to 0.79] vs 0.69 [0.52 to 0.79]) and AHS (0.52 [0.35 to 0.69] vs 0.61 [0.49 to 0.70]). Of the 36 YNHHS patients on mavacamten therapy, the median AI-ECG score before starting mavacamten was 0.41 (0.22 to 0.77), which decreased significantly to 0.28 (0.11 to 0.50, p <0.001 by Wilcoxon signed-rank test) at the end of a median follow-up period of 237 days. In conclusion, we observed a lack of improvement in AI-based HCM score with SRT, in contrast to a significant decrease with mavacamten. Our approach suggests the potential role of AI-ECG for serial point-of-care monitoring of pathophysiologic improvement after medical therapy in HCM using ECG images.

2024-12-16·EUROPEAN HEART JOURNAL

Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy

Article

作者: Hegde, Sheila M ; Lakdawala, Neal K ; Oręziak, Artur ; Jensen, Morten K ; Wheeler, Matthew T ; Shah, Ashish ; Seidler, Tim ; Fox, Shawna ; Garcia-Pavia, Pablo ; Barriales-Villa, Roberto ; Abraham, Theodore P ; Wojakowski, Wojciech ; Masri, Ahmad ; Wang, Andrew ; Choudhury, Lubna ; Balaratnam, Ganesh ; Owens, Anjali T ; Hagege, Albert ; Olivotto, Iacopo

Abstract:

Background and Aims:

Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term effects of mavacamten.

Methods:

Participants from EXPLORER-HCM (NCT03470545) could enrol in MAVA-LTE upon study completion.

Results:

At the latest data cut-off, 211 (91.3%) of the 231 patients originally enrolled in MAVA-LTE still received mavacamten. Median (range) time on study was 166.1 (6.0–228.1) weeks; 185 (80.1%) and 99 (42.9%) patients had completed the Week 156 and 180 visits, respectively. Sustained reductions from baseline to Week 180 occurred in left ventricular outflow tract gradients [mean (standard deviation): resting, −40.3 (32.7) mmHg; Valsalva, −55.3 (33.7) mmHg], N-terminal pro B-type natriuretic peptide [median (interquartile range): −562 (−1162.5, −209) ng/L], and EQ-5D-5L score [mean (standard deviation): 0.09 (0.17)]. Mean left ventricular ejection fraction (LVEF) decreased from 73.9% (baseline) to 66.6% (Week 24) and 63.9% (Week 180). At Week 180, 74 (77.9%) of the 95 patients improved by at least one New York Heart Association class from baseline. Over 739 patient-years exposure, 20 patients (8.7%; exposure-adjusted incidence: 2.77/100 patient-years) experienced 22 transient reductions in LVEF to <50% resulting in temporary treatment interruption (all recovered LVEF of ≥50%). Five (2.2%) patients died (all considered unrelated to mavacamten).

Conclusions:

Long-term mavacamten treatment resulted in sustained improvements in cardiac function and symptoms in patients with obstructive HCM, with no new safety concerns identified. Transient, reversible reductions in LVEF were observed in a small proportion of patients during long-term follow-up.

2024-12-01·JOURNAL OF CARDIAC FAILURE

Association between age or duration of diagnosis in obstructive hypertrophic cardiomyopathy and response to mavacamten treatment: Exploratory analysis of the EXPLORER-HCM trial

Article

作者: Wojdyla, Daniel M ; Lakdawala, Neal K ; Nilles, Ester Kim ; Sehnert, Amy ; Owens, Anjali Tiku ; Bach, Richard G ; Wang, Andrew ; Abraham, Theodore P ; Cresci, Sharon ; Saberi, Sara

BACKGROUND AND AIMS:

In patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM), it is unclear if response to cardiac myosin inhibition varies with older age or a longer duration of diagnosis. This study evaluated the response of these subgroups to mavacamten therapy for all primary, secondary, and exploratory endpoints in the EXPLORER-HCM trial (ClinicalTrials.gov: NCT03470545).

METHODS:

Patients were stratified by age (≤60 vs. >60 years) and duration of HCM diagnosis (≤5 vs. >5 years). To estimate treatment differences and evaluate age and diagnosis duration by treatment interaction, analysis of covariance was used to model changes in continuous endpoints and a generalized linear model was used for binary endpoints.

RESULTS:

Older patients were more frequently female (53% vs. 29%), with a lower prevalence of pathogenic/likely pathogenic HCM gene variants (17% vs. 36%), lower mean peak oxygen consumption (pVO₂) (17.6 vs. 21.1 ml/kg/min), and a higher mean NT-proBNP level (817 vs. 592 ng/L) but similar NYHA classes and quality of life scores. Patients with a longer vs. shorter diagnosis duration had similar mean ages (59.0±11.6 vs. 57.9±12.3 years) but more family history of HCM (38% vs. 16%) and a higher mean NT-pro BNP level (938±118 vs. 494±145 ng/ml). No differences were observed in improvement in peak oxygen consumption, NYHA class, or patient-reported outcomes among older patients and those with a longer duration of diagnosis.

CONCLUSIONS:

In EXPLORER-HCM, mavacamten treatment had a similar benefit for all primary, secondary, and exploratory endpoints in patients with symptomatic, obstructive HCM regardless of age or duration of diagnosis.

297

项与玛伐凯泰相关的新闻（医药）

2024-12-02

·Endpoints

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M

Plus, news about Cytokinetics, Theratechnologies, KisoJi Biotechnology and XOMA Royalty: Senti Bio touts early Phase 1 CAR-NK data, stock soars: Two of three patients who received the low dose of Senti’s treatment achieved a complete response as of the Sept. 19 data cutoff. Senti expects to enroll 20 patients in the study. Its stock rose more than 150% in premarket trading on Monday, and the company also said it secured a $37.6 million PIPE. — Max Gelman China startup nabs $42M Series A: Allink Biotherapeutics, which was founded in 2023, is focused on bispecifics and antibody-drug conjugates. The money will help fund two pipeline programs called ALK201 and ALK202 through Phase 1 trials, as well as push forward other efforts in oncology and immunology. The round was led by Lanchi Ventures. — Max Gelman Cytokinetics’ heart drug gets FDA decision date: The biotech announced that the FDA has set a deadline of Sept. 26 to decide whether to approve aficamten for a heart condition called obstructive hypertrophic cardiomyopathy. The agency currently has no plans to hold an advisory committee. If approved, the treatment would compete with Bristol Myers Squibb’s Camzyos, which is currently the only cardiac myosin inhibitor approved in the US. — Lei Lei Wu Theratechnologies reveals financing: The Montreal biotech said it could get up to $75 million from TD Bank and Investissement Québec via credit facilities. Some of the loans will go toward paying off existing credit facilities and bankroll business development. The company had about $20 million in cash at the end of November. — Kyle LaHucik KisoJi gets $41M to advance TROP2 program: The company plans to use the money to get KJ-103, its lead compound, into Phase 1 testing for solid tumors. Funds include “the conversion of previously funded convertible debentures.” Investissement Québec and Lumira Ventures led the financing. — Max Gelman XOMA’s latest royalty deal: The royalty company bought Pulmokine for $20 million in cash. The move gives XOMA access to a milestone and royalty stream from Pulmokine’s interest in seralutinib, the pulmonary arterial hypertension drug it licensed to Gossamer Bio. The drug is now in Phase 3, with a readout slated for late 2025. — Kyle LaHucik

临床1期临床3期上市批准抗体药物偶联物

2024-12-02

·BioPharmaDive

Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date

Today, a brief rundown of news involving Novocure and Merus, as well as updates from Cytokinetics, Fate Therapeutics and Bluebird bio that you may have missed.Novocure said its electrical field-emitting device alongside chemotherapy helped people with locally advanced pancreatic cancer live longer than those who received only chemo in a Phase 3 trial. Trial participants treated with Novocures therapy survived for an average of just over 16 months, a statistically significant, two-month difference versus chemo alone, the company said. Novocure intends to file for regulatory approval in pancreatic cancer. The device is already cleared to treat glioblastoma, mesothelioma and non-small cell lung cancer. Jonathan GardnerMerus has licensed to Partner Therapeutics U.S. rights to its experimental cancer drug zenocutuzumab for an undisclosed sum, the companies announced Monday. An antibody drug, zenocutuzumab is under Food and Drug Administration review for use treating NRG1 fusion-positive tumors. The agency recently extended its evaluation and now expects to reach a decision on approval by Feb. 4, 2025. Ned PagliaruloThe Food and Drug Administration will decide by Sept. 26, 2025, whether to approve Cytokinetics heart drug aficamten in obstructive hypertrophic cardiomyopathy, the company said Monday. The agency accepted Cytokinetics application, which was based on the results of a Phase 3 trial showing use of aficamten improved exercise capacity for people with the condition. If approved, aficamten will compete with Bristol Myers Squibbs Camzyos, approved in 2022. The announcement follows moves by Cytokinetics to sell partial rights to the drug, including a royalty deal with Royalty Pharma and a Japanese licensing deal with Bayer. Cytokinetics previously had another heart failure drug rejected by the FDA. Jonathan GardnerThe FDA is now formally investigating cases of blood cancer following treatment with Bluebird bios gene therapy Skysona. The Nov. 27 notice from the agency cites cases Bluebird previously reported, details of which were published in October in The New England Journal of Medicine. No new cases or safety information preceded the FDAs announcement, a Bluebird spokesperson confirmed to BioPharma Dive. However, the agency did recommend that providers carefully consider alternative therapies like a hematopoietic stem cell transplant for prospective patients who have a matched donor, due to the blood cancer risk. Ned PagliaruloFate Therapeutics president and CEO Scott Wolchko will retire at the end of the year, ending a nearly decade-long stint running the natural killer cell therapy developer. The company said on Nov. 29 that longtime research chief Bob Valamehr will take over as its head at the start of 2025, with Wolchko transitioning to a strategic adviser. Fate previously only developed cancer therapies. But the company reset in 2023 and, like many of its peers, has made autoimmune disease research a focus as well. One program is now in early-stage testing in lupus. Ben Fidler '

临床3期临床结果基因疗法细胞疗法

2024-11-29

·赛柏蓝

2024年医保谈判，这些药企是最大赢家

特约作者 | 张自然博士责任编辑 | 郑瑶 2024年国家医保谈判结果，于11月28日公布。医保鼓励创新效果显著。关注赛柏蓝，进入主页发消息界面发送【2024医保目录】获取国家基本医疗保险、工伤保险和生育保险药品目录（2024年）PDF~ 01 国产vs进口 2024医保谈判，共新增纳入药品91种，是除2023年外，历年国谈最多的一次。其中，国产药65个，占71%，进口药26个，占29%。纳入国产新药数占比是历次国谈最多的一次。在全链条政策鼓励下，国产创新药发展迅速。 02 企业 2024年医保谈判，共新增纳入药品91种，除2种国家集采中选产品被直接纳入外，其余89种都是通过谈判/竞价纳入，其中，84种为独家品种（独家剂型84个，独家通用名82个）。在这82个独家通用名中，国产药53个（占65%）、进口药29个（占35%）。这82个独家通用名共涉及企业64家，其中，本土企业44家（占69%），外企20家（占31%）。有≥2个独家通用名品种的企业共14家，其中，本土企业8家，外企6家。在这8家本土企业中，除一家Biotech（迪哲（苏州）医药）外，其余都是向创新转型的传统制药企业，包括2家中药企业（江西青峰、济川药业）。 2024年医保谈判，成功纳入医保独家通用名品种数量最多的是瑞士罗氏制药。有4个独家通用名的企业有1家，即罗氏，其法瑞西单抗注射液、玛巴洛沙韦干混悬剂、帕妥珠曲妥珠单抗注射液（皮下注射）、注射用维泊妥珠单抗等4个新药纳入医保；有3个独家通用名的企业有2家，即百时美施贵宝（玛伐凯泰胶囊、瑞普替尼胶囊、氘可来昔替尼片）、宜昌人福（氯巴占片、盐酸氢吗啡酮缓释片、注射用磷丙泊酚二钠）；有2个独家通用名的企业有7家，即4家传统西药企业：恒瑞（富马酸泰吉利定注射液、恒格列净二甲双胍缓释片）；正大天晴（富马酸安奈克替尼胶囊、枸橼酸依奉阿克胶囊）；信立泰（阿利沙坦酯氨氯地平片、苯甲酸福格列汀片）；海思科（苯磺酸克利加巴林胶囊、考格列汀片）； 1家Biotech迪哲（苏州）医药（戈利昔替尼胶囊、舒沃替尼片）；以及2家中药企业，各有1个中成药和1个西药谈判成功，即江西青峰（枳实总黄酮片、布立西坦片）、济川药业（小儿豉翘清热糖浆、盐酸非索非那定干混悬剂）。附：2024版新增医保品种名单 END 内容沟通：郑瑶（13810174402）左下角「关注账号」，右下角「在看」，防止失联

引进/卖出

100 项与玛伐凯泰相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14921

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
梗阻性肥厚型心肌病	美国	Bristol Myers Squibb Co.	2022-04-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非梗阻性肥厚型心肌病	临床3期	美国	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	中国	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	日本	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	澳大利亚	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	奥地利	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	比利时	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	巴西	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	加拿大	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	捷克	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	丹麦	Bristol Myers Squibb Co.	2022-12-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05414175 (HORIZON-HCM, CTgov)	临床3期	梗阻性肥厚型心肌病	38	Mavacamten	憲製襯鬱繭網蓋憲觸夢(構獵願鏇窪蓋艱選鏇鏇) = 膚窪膚餘夢製廠鹹鬱製網遞願膚艱憲憲範淵廠 (夢鏇鬱鑰築鏇廠齋醖積, 鬱構簾鹹壓壓選鹽醖獵 ~ 衊構鑰網範膚窪膚遞淵) 更多	-	2024-12-04
NCT03470545 (EXPLORER-HCM, Pubmed \| J Card Fail)	临床3期	梗阻性肥厚型心肌病	-	mavacamten (Age ≤60 years)	製選膚窪壓餘鏇鹽鬱遞(醖顧構積遞願構蓋鑰觸) = 餘顧鑰蓋糧鬱鬱糧積願繭壓範衊觸壓範構願製 (網窪壓觸製鏇範憲遞衊 ) 更多	积极	2024-12-01
				mavacamten (Age >60 years)	製選膚窪壓餘鏇鹽鬱遞(醖顧構積遞願構蓋鑰觸) = 鹽醖製廠醖遞築製蓋餘繭壓範衊觸壓範構願製 (網窪壓觸製鏇範憲遞衊 ) 更多
NCT05174416 (CTgov)	临床3期	梗阻性肥厚型心肌病	81	Mavacamten (Mavacamten)	選膚淵夢獵觸範製繭願(窪艱鑰廠積獵夢選膚願) = 獵觸願衊醖衊餘膚壓觸繭獵廠醖觸窪醖構餘積 (繭築夢範獵糧願顧簾醖, 繭襯鏇膚範繭壓襯壓築 ~ 膚壓鹹簾範觸窪窪窪艱) 更多	-	2024-09-19
				Placebo (Placebo)	選膚淵夢獵觸範製繭願(窪艱鑰廠積獵夢選膚願) = 衊膚顧醖鑰鑰襯壓鏇繭繭獵廠醖觸窪醖構餘積 (繭築夢範獵糧願顧簾醖, 鹹蓋鹽繭觸簾遞壓網構 ~ 構網顧獵廠鹹網鹽夢顧) 更多
NCT03723655 (EXPLORER-LTE, BusinessWire) 人工标引	临床3期	梗阻性肥厚型心肌病	251	CAMZYOS® (mavacamten)	鏇網鏇鹹鹽選獵夢簾顧(膚醖選廠鑰廠齋壓遞齋) = 築願構廠積襯遞顧獵淵廠廠範構廠蓋獵壓顧遞 (獵積積觸艱醖獵繭淵憲 ) 更多	积极	2024-09-01
Pubmed \| JACC Cardiovasc Imaging	N/A	肥大型心肌病	-	Mavacamten	廠鹹遞鹽顧襯憲鹽觸壓(積廠壓顧鏇網遞鏇衊積) = 繭築遞齋衊蓋網遞鬱鹽選糧鹹窪夢鏇觸觸願蓋 (鑰壓艱齋遞獵餘積遞鬱 ) 更多	-	2024-09-01
				Placebo	廠鹹遞鹽顧襯憲鹽觸壓(積廠壓顧鏇網遞鏇衊積) = 獵鹹鹹簾齋淵繭積遞淵選糧鹹窪夢鏇觸觸願蓋 (鑰壓艱齋遞獵餘積遞鬱 ) 更多
ESC2024	N/A	梗阻性肥厚型心肌病	-	Mavacamten 2.5 mg	窪遞糧艱鬱鹹積顧鑰衊(鏇鏇艱憲齋構糧鏇餘膚) = 製鑰獵鏇蓋襯鏇窪願構鹹鑰艱製選蓋廠觸夢鏇 (願遞齋餘淵齋衊齋選襯 ) 更多	-	2024-08-31
				Mavacamten 5 mg	窪遞糧艱鬱鹹積顧鑰衊(鏇鏇艱憲齋構糧鏇餘膚) = 糧襯構鹽鹽壓齋鬱鏇選鹹鑰艱製選蓋廠觸夢鏇 (願遞齋餘淵齋衊齋選襯 ) 更多
NCT05135871 (CTgov)	临床1期	肥大型心肌病	45	Mavacamten (Cohort 1: Mavacamten 15 mg)	鹽鹹遞窪糧壓觸獵廠遞(觸顧夢夢鹽蓋廠繭餘壓) = 願廠繭醖壓獵襯製觸構廠鹽艱夢鏇襯選鑰蓋壓 (齋構鏇淵壓願築顧醖觸, 範餘艱衊夢製衊積鹽憲 ~ 醖糧襯鹹膚製製淵鑰餘) 更多	-	2024-07-25
				Mavacamten (Cohort 2: Mavacamten 25 mg)	鹽鹹遞窪糧壓觸獵廠遞(觸顧夢夢鹽蓋廠繭餘壓) = 網選淵齋獵鏇選窪膚願廠鹽艱夢鏇襯選鑰蓋壓 (齋構鏇淵壓願築顧醖觸, 鹽簾積構憲鏇觸遞遞範 ~ 蓋糧齋獵製衊築願鹹廠) 更多
NCT03496168 (PIONEER-OLE, Pubmed \| J Am Heart Assoc) 人工标引	临床2期	梗阻性肥厚型心肌病 NT-proBNP	12	Mavacamten 5 mg	壓積築觸蓋選簾憲壓顧(壓製選構簾鑰遞構衊鏇) = Treatment-emergent adverse events were predominantly mild/moderate. One patient had an isolated reduction in left ventricular ejection fraction to 47%, which recovered and remained normal with continued treatment at a reduced dose. 壓顧膚壓淵鑰蓋積觸範 (淵鏇淵餘齋構鏇廠選觸 ) 更多	积极	2024-04-09
NCT03470545 (EXPLORER-HCM, Pubmed \| JACC Heart Fail)	临床3期	高血压 \| 梗阻性肥厚型心肌病	251	Mavacamten	築築願餘廠醖觸積簾壓(製觸選願製獵蓋鑰醖繭) = 築襯製憲製襯憲獵鹽糧鹹艱醖築醖襯襯壓鹹鏇 (遞願鑰糧構膚憲鹹憲窪 ) 更多	-	2024-03-01
				Placebo	築築願餘廠醖觸積簾壓(製觸選願製獵蓋鑰醖繭) = 醖簾憲繭觸觸廠齋壓獵鹹艱醖築醖襯襯壓鹹鏇 (遞願鑰糧構膚憲鹹憲窪 ) 更多
NCT03470545 (EXPLORER-HCM, Pubmed \| Circulation) 人工标引	临床3期	梗阻性肥厚型心肌病 plasma NT-proBNP	-	Mavacamten	夢鹹構製獵壓鑰築鹽壓(夢壓簾願積膚鏇網壓艱) = 積構糧齋顧襯範蓋憲鏇鹽淵鹹鹽憲簾願餘範構 (構顧範襯範顧壓繭網襯 ) 更多	相似	2024-02-13
				mavacamten	夢鹹構製獵壓鑰築鹽壓(夢壓簾願積膚鏇網壓艱) = 製襯顧衊廠鹽願壓窪遞鹽淵鹹鹽憲簾願餘範構 (構顧範襯範顧壓繭網襯 ) 更多